Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Hiddingh, Lotte ^a   Raktoe, Rajiv S ^a   Jeuken, Judith ^b   Hulleman, Esther ^a   Noske, David P ^a   Kaspers, Gertjan J L ^a   Vandertop, W Peter ^a   Wesseling, Pieter ^a,c   Wurdinger, Thomas ^a,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Stichting Laboratoria voor Pathologie en Medische Microbiologie   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; DACARBAZINE; MESSENGER RNA; MICRORNA; PHF6 PROTEIN, HUMAN; TEMOZOLOMIDE;

ANALOGS AND DERIVATIVES; DRUG RESISTANCE; GENE REGULATORY NETWORK; GENETICS; GLIOBLASTOMA; HUMAN; TUMOR CELL LINE; UPREGULATION;

CARRIER PROTEINS; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GENE REGULATORY NETWORKS; GLIOBLASTOMA; HUMANS; MICRORNAS; RNA, MESSENGER; UP-REGULATION;

EID: 84902338069     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05260     Document Type: Article

References (53)

1. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352, 987-96 (2005). (Pubitemid 40349501)
2. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-66 (2009).
3. Roos, W. P. et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 26, 186-97 (2007). (Pubitemid 46095730)
4. Caporali, S. et al. DNA Damage Induced by Temozolomide Signals to both ATM and ATR: Role of the Mismatch Repair System. Mol Pharmacol. 66, 478-491 (2004). (Pubitemid 39329246)
5. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352, 997-1003 (2005). (Pubitemid 40349502)
6. Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B. & Herman, J. G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59, 793-797 (1999). (Pubitemid 29086728)
7. Qian, X. C. & Brent, T. P. Methylation hot spots in the 59 flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res. 57, 3672-3677 (1997). (Pubitemid 27381206)
8. Cahill, D. P. et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 13, 2038-45 (2007). (Pubitemid 46649870)
9. Hunter, C. et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 66, 3987-91 (2006).
10. Yip, S. et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 15, 4622-9 (2009).
11. Ujifuku, K. et al. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett. 296, 241-8 (2010).
12. Li, P. et al. MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells. J Biomed Res. 24, 436-43 (2010).
13. Shi, L. et al. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl- 2 ratio and caspase-3 activity. Brain Res. 1352, 255-64 (2010).
14. Shi, L. et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int JOncol. 40, 119-29 (2012).
15. Yang, Y. -P. et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials. 33, 1462-76 (2012).
16. Wong, S. T. S. et al. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res. 32, 2835-41 (2012).
17. Asuthkar, S., Velpula, K. K., Chetty, C., Gorantla, B. & Rao, J. S. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget. 3, 1439-54 (2012).
18. Wang, J., Sai, K., Chen, F. & Chen, Z. miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol. 72, 147-58 (2013).
19. Comincini, S. et al. microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells. Cancer Biol Ther. 14, 574-86 (2013).
20. Munoz, J. L. et al. Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cellderived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids. 2, e126 (2013).
21. Tang, H. et al. The miR-183/96/182 cluster regulates oxidative apoptosis and sensitizes cells to chemotherapy in gliomas. Curr Cancer Drug Targets. 13, 221-31 (2013).
22. Chen, L. et al. Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol Rep. 27, 854-60 (2012).
23. He, L. & Hannon, G. J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 5, 522-31 (2004). (Pubitemid 38868508)
24. Huang, G. T., Athanassiou, C. & Benos, P. V. mirConnX: condition-specific mRNA-microRNA network integrator. Nucleic Acids Res. 39, W416-23 (2011).
25. Sales, G. et al. MAGIA, a web-based tool for miRNA and Genes Integrated Analysis. Nucleic Acids Res. 38, W352-9 (2010).
26. Nam, S. et al. MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression. Nucleic Acids Res. 37, W356-62 (2009).
27. Huang, J. C., Morris, Q. D. & Frey, B. J. Bayesian inference of MicroRNA targets from sequence and expression data. J Comput Biol. 14, 550-63 (2007). (Pubitemid 47047813)
28. Cascione, L. et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One. 8, e55910 (2013).
29. Kusko, R. L. et al. Comprehensive genomic profiling of the lung transcriptome in emphysema and idiopathic pulmonary fibrosis using RNA-Seq. BMC Proc. 6, P21 (2012).
30. Winter, J., Jung, S., Keller, S., Gregory, R. I. & Diederichs, S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 11, 228-34 (2009).
31. Esquela-Kerscher, A. & Slack, F. J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6, 259-69 (2006).
32. Filipowicz, W., Bhattacharyya, S. N. & Sonenberg, N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 9, 102-14 (2008).
33. Hiddingh, L. et al. EFEMP1 induces c-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget. 5, 363-74 (2014).
34. Berchtold, N. C. et al. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A. 105, 15605-10 (2008).
35. Murat, A. et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 26, 3015-24 (2008).
36. Sun, L. et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 9, 287-300 (2006).
37. Gravendeel, L. A. M. et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 69, 9065-72 (2009).
38. Freije, W. A. et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64, 6503-10 (2004). (Pubitemid 39297907)
39. Uhlen, M. et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 28, 1248-50 (2010).
40. Hecker, N. et al. A new algorithm for integrated analysis of miRNA-mRNA interactions based on individual classification reveals insights into bladder cancer. PLoS One. 8, e64543 (2013).
41. Bar-Joseph, Z., Gitter, A. & Simon, I. Studying and modelling dynamic biological processes using time-series gene expression data. Nat Rev Genet. 13, 552-64 (2012).
42. Schulz, M. H. et al. Reconstructing dynamic microRNA-regulated interaction networks. Proc Natl Acad Sci U S A. 110, 15686-91 (2013).
43. Wang, J. et al. PHF6 regulates cell cycle progression by suppressing ribosomal RNA synthesis. J Biol Chem. 288, 3174-83 (2013).
44. Jantzen, H. M., Admon, A., Bell, S. P. & Tjian, R. Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins. Nature. 344, 830-6 (1990).
45. Todd, M. A. M. & Picketts, D. J. PHF6 interacts with the nucleosome remodeling and deacetylation (NuRD) complex. J Proteome Res. 11, 4326-37 (2012).
46. Zhang, Y. et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13, 1924-35 (1999). (Pubitemid 29407360)
47. Mavrakis, K. J. et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet. 43, 673-8 (2011).
48. Van Vlierberghe, P. et al. PHF6mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 42, 338-42 (2010).
49. Van Vlierberghe, P. et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 25, 130-4 (2011).
50. Zhang, Y. & Lu, H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 16, 369-77 (2009).
51. Bursać, S. et al. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc Natl Acad Sci U S A. 109, 20467-72 (2012).
52. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell. 88, 323-31 (1997). (Pubitemid 27131374)
53. Nam, S., Long, X., Kwon, C., Kim, S. & Nephew, K. P. An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells. BMC Genomics. 13, 732 (2012).